Roivant discontinues lung disease drug; Bio-Thera, Intas make biosimilar dealnews2025-02-10T15:21:51+00:00February 10th, 2025|Endpoints News|
AffyImmune’s layoffs; Henlius makes a biosimilar deal with Dr. Reddy’snews2025-02-06T15:43:32+00:00February 6th, 2025|Endpoints News|
Bristol Myers, Kyowa Kirin disclose layoffsnews2025-02-05T16:26:26+00:00February 5th, 2025|Endpoints News|
Turnstone stops TIL studies; GH Research’s $150M offeringnews2025-02-04T15:39:12+00:00February 4th, 2025|Endpoints News|
Tectonic to raise $185M; Acelyrin drops rights to Affibody drugnews2025-02-03T15:04:37+00:00February 3rd, 2025|Endpoints News|
Ironwood’s layoffs; Shionogi’s RSV pill succeeds in Phase 2news2025-01-30T15:50:07+00:00January 30th, 2025|Endpoints News|
Curie.Bio has a new $340M fund; Layoffs at Benchling, I-Mabnews2025-01-29T15:10:17+00:00January 29th, 2025|Endpoints News|
Akero, 89bio disclose public offerings; BioAge drops Phase 2 obesity drugnews2025-01-28T14:53:04+00:00January 28th, 2025|Endpoints News|
Allakos restructures after Phase 1 failure; AB2 inks deal with Nippon Shinyakunews2025-01-27T15:25:04+00:00January 27th, 2025|Endpoints News|
Boehringer merges cancer vaccine and oncolytic virus teams; Dantari sells off assetsnews2025-01-24T15:16:32+00:00January 24th, 2025|Endpoints News|
